SAB Biotherapeutics to Showcase SAB-142 Data at EASD 2026
Event summary
- SAB Biotherapeutics will present Phase 1 data on SAB-142 at the 62nd EASD Annual Meeting in Milan, September 28 - October 2, 2026.
- Presentations will highlight SAB-142's mechanism of action, redosing safety, and early C-peptide preservation evidence in T1D patients.
- SAB-142 is currently in a registrational Phase 2b trial (SAFEGUARD) for newly diagnosed Stage 3 T1D patients.
- The company's proprietary technology uses transchromosomic cattle to produce fully human immunoglobulins.
The big picture
SAB Biotherapeutics' presentation at EASD 2026 comes as the diabetes research community increasingly focuses on disease-modifying therapies that preserve insulin production. The company's proprietary platform for producing fully human immunoglobulins represents a potential breakthrough in treating autoimmune diseases, though it faces competition from established treatments like rabbit ATG. The success of SAB-142 could validate this novel approach and open new avenues for autoimmune disease treatment.
What we're watching
- Clinical Efficacy
- How SAB-142's early C-peptide preservation data will position it against existing T1D treatments.
- Regulatory Pathway
- The pace at which SAFEGUARD trial results could accelerate SAB-142's regulatory approval process.
- Market Differentiation
- Whether SAB-142's fully human immunoglobulin approach will provide a competitive advantage in the autoimmune disease space.